Stoke Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 16, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 16, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGNA TURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.
| STOKE THERAPEUTICS, INC. | ||
| Date: March 16, 2026 | By: | /s/ Ian F. Smith |
|---|---|---|
| Ian F. Smith | ||
| Chief Executive Officer | ||
| (Principal Executive Officer) | ||
POWER OF ATTORNEY
Each person whose individual signature appears below hereby authorizes and appoints Ian F. Smith and Thomas E. Leggett, and each of them, with full power of substitution and re-substitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this Annual Report on Form 10-K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue thereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Ian F. Smith | Chief Executive Officer and Director | March 16, 2026 |
| Ian F. Smith | (Principal Executive Officer) | |
| /s/ Thomas E. Leggett | Chief Financial Officer | March 16, 2026 |
| Thomas E. Leggett | (Principal Financial and Accounting Officer) | |
| /s/ Julie A. Smith | Director | March 16, 2026 |
| Julie A. Smith | ||
| /s/ Seth L. Harrison | Director | March 16, 2026 |
| Seth L. Harrison, M.D. | ||
| /s/ Adrian R. Krainer | Director | March 16, 2026 |
| Adrian R. Krainer, Ph.D. | ||
| /s/ Arthur A. Levin | Director | March 16, 2026 |
| Arthur A. Levin, Ph.D. | ||
| /s/ Edward M. Kaye M.D. | Director | March 16, 2026 |
| Edward M. Kaye M.D | ||
| /s/ Jennifer C. Burstein | Director | March 16, 2026 |
| Jennifer C. Burstein | ||
| /s/ Garry E. Menzel | Director | March 16, 2026 |
| Garry E. Menzel | ||
| /s/ Arthur O. Tzianabos | Chairman of the Board of Directors | March 16, 2026 |
| Arthur O. Tzianabos, Ph.D. | ||
STOKE THERAPEUTICS, INC.
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Page | |
|---|---|
| Report of Independent Registered Public Accounting Firm | 97 |
| Consolidated balance sheets | 99 |
| Consolidated statements of operations and comprehensive loss | 100 |
| Consolidated statements of stockholders’ equity | 101 |
| Consolidated statements of cash flows | 102 |
| Notes to consolidated financial statements | 103 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.